Every 8-K that IDEXX Laboratories (IDXX) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow IDXX and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full IDXX filings page.
IDEXX Laboratories reported strong second‑quarter 2026 results, with revenue of $1,217 million, up 10% as reported and 9% organic versus the prior year. Diluted EPS was $4.27, an 18% increase, while comparable EPS grew 15% to $4.07. Gross margin reached 64.0% and operating margin 35.0%, both expanding 140 basis points year over year.
Growth was broad-based: Companion Animal Group revenue rose 9% as reported and 8.7% organic, driven by 11.0% reported and 10.3% organic growth in CAG Diagnostics recurring revenue, while Water revenue increased 14.8% reported and 13.0% organic and LPD revenue grew 10.8% reported and 9.0% organic.
The company raised its 2026 outlook, guiding revenue to $4,700–$4,745 million with 9.1%–10.3% reported growth and 8.5%–9.7% organic growth. It now expects operating margin of 32.3%–32.5% and EPS of $14.69–$14.94, implying 12%–14% reported and 13%–15% comparable EPS growth for the year.
IDEXX Laboratories, Inc. reported that shareholders approved key governance changes at the 2026 annual meeting. Amendments to the Amended and Restated Certificate of Incorporation will declassify the Board over three years and move to annual elections for all directors beginning with the 2029 annual meeting.
Shareholders also approved giving investors who own at least 25% of the company’s stock continuously for at least one year the right to require the company to call a special shareholder meeting, subject to conditions in the By-Laws. Three Class II directors were elected through 2029, PricewaterhouseCoopers LLP was ratified as auditor, executive pay received advisory approval, and a separate shareholder proposal on special meeting rights was not approved.
IDEXX Laboratories reported strong first quarter 2026 results, with revenue of $1.14 billion, up 14% as reported and 11% organically. Growth was led by Companion Animal Group revenue, including 14% reported and 11% organic CAG Diagnostics recurring revenue growth, and 33% reported growth in diagnostics capital instruments.
Diluted EPS was $3.47, up 17% as reported and 15% on a comparable basis. Gross margin improved to 63.4% and operating margin to 31.8%. Free cash flow was $234 million. Management raised full-year 2026 guidance, targeting revenue of $4.675–$4.760 billion, organic growth of 7.7%–9.7%, and EPS of $14.45–$14.90.
IDEXX Laboratories announced that Executive Vice President, Global Strategy and Commercial, Nimrata Hunt, PhD, will leave her role effective April 13, 2026, then serve as a special advisor on an as‑needed basis until July 13, 2026.
Under a separation agreement, IDEXX will provide salary continuation for 104 weeks totaling $1,230,000 and pay her target annual bonus for two years totaling $984,000, alongside a $50,000 COBRA-related lump sum, $10,000 in transition assistance and up to $6,000 per year for 2025 and 2026 tax or financial planning services.
Unvested stock options, restricted stock units and performance stock units will be forfeited as of the final employment date, while vested stock options remain exercisable under existing award terms. IDEXX characterizes the move as a termination without cause tied to elimination of her position and obtained a broad release, non‑disparagement and ongoing cooperation commitments.
IDEXX Laboratories, Inc. reported that director M. Anne Szostak has notified the company of her intention to retire from its Board of Directors. Her retirement will be effective immediately following the company’s 2026 Annual Meeting of Stockholders, scheduled for May 12, 2026.
The company stated that Ms. Szostak’s decision does not result from any disagreement regarding operations, policies, or practices. She has served on the Board since 2012, and the company expressed appreciation for her contributions and leadership during this period.
Upon her retirement, the Board will reduce the size of Class III directors in line with its amended and restated by-laws. However, the overall Board size will not change because of the previously announced appointment of Michael G. Erickson, PhD as a Class II director immediately following the 2026 Annual Meeting.
IDEXX Laboratories, Inc. filed a Form 8-K after announcing its financial results for the quarter and year ended December 31, 2025. The detailed results are provided in a press release furnished as Exhibit 99.1.
The company specifies that this earnings information is furnished under Item 2.02 of Form 8-K and is not deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934. The report is signed by Andrew Emerson, Executive Vice President, Chief Financial Officer and Treasurer.
IDEXX Laboratories is planning a CEO transition. Jonathan (Jay) Mazelsky will step down as President and Chief Executive Officer on May 12, 2026 and become Executive Chair of the Board until his planned retirement following the annual shareholder meeting in May 2027. Michael (Mike) Erickson, PhD, currently Executive Vice President and General Manager of Global Point of Care Diagnostics and Telemedicine, will become President and CEO and join the Board as a Class II director on the same date.
Erickson’s CEO terms include a $1,000,000 annual base salary, an annual bonus targeted at 120% of base salary, and a 2026 long‑term equity incentive with a target grant value of at least $7.8 million split between stock options and performance RSUs. His amended change‑in‑control agreement provides cash severance of up to three times salary and average bonus plus benefit continuations and accelerated vesting on time‑based equity after a qualifying change‑in‑control termination. Mazelsky, as Executive Chair, will receive a $1,150,000 base salary and an incentive structure tied to 2026 performance and a time‑vesting RSU grant with a target value of at least $8.275 million.
IDEXX Laboratories entered into Amendment No. 2 to its fourth amended and restated credit agreement, dated November 12, 2025. The amendment adds a three‑year term loan facility and extends the revolving credit facility maturity to five years from the closing date.
The credit arrangement now consists of an unsecured $1.0 billion revolver and an unsecured $250 million term loan, with flexibility to add up to $250 million in incremental revolving commitments and/or term loans. Borrowings may be used for general corporate purposes.
Interest is benchmarked to currencies and tenors selected, with margins tied to the consolidated leverage ratio: for U.S. dollars, base rate or Adjusted Term SOFR/Daily Simple SOFR with margins ranging from 0.0%–1.375%. Comparable benchmarks apply for CAD (PRIMCAN/Term CORRA), EUR (EURIBOR) and AUD (BBSY). Obligations are guaranteed by certain U.S. subsidiaries, with future material U.S. subsidiaries required to guarantee. Covenants include a consolidated leverage ratio and customary negative covenants; events of default are customary, including a change of control.
IDEXX Laboratories, Inc. announced quarterly results for the period ended September 30, 2025. The company furnished a press release as Exhibit 99.1 with additional details. The information was provided under Item 2.02 of Form 8‑K and is being furnished, not filed, meaning it is not subject to Section 18 liability and is not incorporated into other filings unless specifically referenced.
IDEXX Laboratories announced the election of Karen Peacock to its Board of Directors in a press release dated October 7, 2025. The election was disclosed on Form 8-K filed with the Commission and attached as Exhibit 99.1. The filing is signed by Sharon E. Underberg, Executive Vice President, General Counsel and Corporate Secretary. No additional details about director background, committee assignments, or changes to board composition were included in the filing.